The Strange Pathology of Uterine Sarcomas

Angelo Paolo Dei Tos MD
Department of Oncology
Treviso, Italy
apdeitos@ulss.tv.it
Disclosure slide

No conflicts of interests to declare
Uterine Sarcomas

- **Endometrial Stromal Tumors**
  - Endometrial stromal nodule
  - Endometrial stromal sarcoma
  - Undifferentiated endometrial sarcoma

- **Smooth muscle tumors**
  - Leiomyoma and variants
  - STUMP
  - Leiomyosarcoma

- **Mixed epithelial/mesenchymal tumors**
  - Adenosarcoma
  - Carcinosarcoma (MMMT)
Endometrial stromal sarcoma

- “Low grade” disappeared from label
- Middle-aged women complaining vaginal bleeding or abdominal pain
- Intracavitary fleshy polyp or intramural mass
- Nodular or diffuse; neoplastic plugs in myometrial or parametrical veins
Endometrial stromal sarcoma

- $\frac{1}{3} \Rightarrow$ extrauterine pelvic extension at diagnosis
- Rarely presentation at metastatic sites (usually ovary)
- Occasionally association with prolonged estrogenic stimulation, tamoxifen treatment, or prior pelvic irradiation
Permeation of myometrium

Endometrial stromal cells

< 3 mits/10PF

Vascular invasion
Endometrial stromal sarcoma

- OS at 5 years (Stage I) approx 95%
- Local recurrence up to 25%
- Lung mets > 10 years
- No predictive morphological parameters
- Mitotic activity not used as a prognostic tool
Endometrial Stromal Nodule

- Benign
- Well circumscribed not encapsulated
- Finger-like projections into myometrium not exceeding 3 mm allowed
- No vascular invasion
- Diagnosis not possible in curettage specimen
- Presence of infiltrative margins or vascular permeation are mostly found in the hysterectomy specimen
EST with sex cord-like differentiation

• Type I (ESS with sex cord component):
  – Sex cord component = no prognostic significance

• Type II (UTROSCT)
  – solid, well circumscribed myometrial masses
  – variety of epithelial and stromal patterns resembling granulosa cell and Sertoli cell tumors:
    – Very good prognosis
    – Distinct neoplasm? (lack JAZF1-JJAZ1 fusion)
Endometrioid differentiation

Smooth muscle differentiation
Undifferentiated Endometrial Sarcoma

- Postmenopausal women
- Fleshy masses with hemorrhage and necrosis
- High grade morphology
- Destructive but not permeative (ESS)
- No endometrial stromal differentiation
- Very aggressive behavior
- Diagnosis of exclusion
  - No distinctive line of differentiation
LG vs. HG ESS

- The diagnosis of HIGH GRADE ESS can only be established if areas of LOW GRADE ESS are identified.
- Mitotic activity SHOULD NOT BE USED to separate between low-grade and high-grade ESS.
Cytogenetic alterations in EST

...from collagenase-disaggregated tumor cells, according to the procedures previously described [4, 5].

Only one of 11 G-banded metaphases analyzed showed a normal female karyotype. The remaining ten cells were abnormal. A balanced translocation between chromosomes 7 and 17, at bands p15–21 and q12–21, respectively, was always found, and it was the only chromosome change in three cells. In five cells, the second chromosome 7 was replaced by a marker chromosome containing almost all the long arm of a chromosome 7, and the remaining three abnormal metaphases displayed a third abnormality such as a dicentric chromosome replacing two normal chromosome 7s.

- Recurrent translocation t(7;17)(p15;q21)
  - JAZF1 - JJAZ1
- t(10;17) (q22;p13) identified in ESS with high grade features or clinically aggressive behavior
  - YWHAE-FAM22A/B
14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma

Cheng-Han Lee<sup>a,b,1</sup>, Wen-Bin Ou<sup>a,1</sup>, Adrian Mariño-Enriquez<sup>b</sup>, Meijun Zhu<sup>a</sup>, Mark Mayeda<sup>a</sup>, Yuexiang Wang<sup>a</sup>, Xiangqian Guo<sup>c</sup>, Alayne L. Brunner<sup>c</sup>, Frédéric Amant<sup>d</sup>, Christopher A. French<sup>e</sup>, Robert B. West<sup>e</sup>, Jessica N. McAlpine<sup>e</sup>, C. Blake Gilks<sup>e</sup>, Michael B. Yaffe<sup>f</sup>, Leah M. Prentice<sup>g</sup>, Andrew McPherson<sup>h</sup>, Steven J. M. Jones<sup>h</sup>, Marco A. Marra<sup>h</sup>, Sohrab P. Shah<sup>g</sup>, Matt van de Rijn<sup>i</sup>, David G. Huntsman<sup>g</sup>, Paola Dal Cin<sup>j</sup>, Maria Debiec-Rychter<sup>j</sup>, Marisa R. Nucci<sup>j</sup>, and Jonathan A. Fletcher<sup>a,2</sup>

<sup>a</sup>Department of Pathology, Brigham and Women’s Hospital, Boston, MA 02115; <sup>b</sup>Department of Pathology, Vancouver General Hospital, Vancouver, BC, Canada V5Z 4E3; <sup>c</sup>Department of Pathology, Stanford University Medical Center, Stanford, CA 94305; <sup>d</sup>Center for Human Genetics, Catholic University of Leuven, B-3000 Leuven, Belgium; <sup>e</sup>Department of Gynecology and Obstetrics, University of British Columbia, Vancouver, BC, Canada V5Z 1M9; <sup>f</sup>Departments of Biology and Biological Engineering, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139; <sup>g</sup>Centre for Translational and Applied Genomics, British Columbia Cancer Agency, Vancouver, BC, Canada V5Z 4E6; and <sup>h</sup>Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada V5Z 1L3

Edited by Bert Vogelstein, Johns Hopkins University, Baltimore, MD, and approved December 7, 2011 (received for review September 22, 2011)
The Clinicopathologic Features of YWHAE-FAM22 Endometrial Stromal Sarcomas: A Histologically High-grade and Clinically Aggressive Tumor

Cheng-Han Lee, MD, PhD,*† Adrian Mariño-Enriquez, MD,* Wenbin Ou, PhD,* Meijun Zhu, PhD,* Rola H. Ali, MD,† Sarah Chiang, MD,‡ Frédéric Amant, MD,§ C. Blake Gilks, MD,† Matt van de Rijn, MD, PhD,‖ Esther Oliva, MD,‡ Maria Debiec-Rychter, MD,¶ Paola Dal Cin, PhD,* Jonathan A. Fletcher, MD,* and Marisa R. Nucci, MD*
Cyclin D1 as a Diagnostic Immunomarker for Endometrial Stromal Sarcoma With YWHAE-FAM22 Rearrangement

Cheng-Han Lee, MD, PhD,* † Rola H. Ali, MD,* † Marjan Rouzbahman, MD,‡
Adrian Marino-Enriquez, MD,§ Meijun Zhu, PhD,§ Xiangqian Guo, PhD,‖ Alayne L. Brunner, PhD,‖
Sarah Chiang, MD,¶ Samuel Leung, MSc,* † Nataliya Nelnyk, MSc,# David G. Huntsman, MD,#
C. Blake Gilks, MD,* † Torsten O. Nielsen, MD, PhD,* † Paola Dal Cin, PhD,§
Matt van de Rijn, MD, PhD,‖ Esther Oliva, MD,¶ Jonathan A. Fletcher, MD,§ and Marisa R. Nucci, MD,§

(Am J Surg Pathol 2012;36:1562–1570)
EST Classification

- **LG ESS**
  - Mostly associated with JAZF1-JJAZ1
  - CD10 +; ER/PR +

- **HG ESS**
  - Mostly associated with YWHAE-FAM22A/B

- **Undifferentiated endometrial sarcoma**
Uterine Leiomyosarcoma

• Most common sarcoma among young women
  – 25% of all uterine malignancies
• Five-year survival: 25 to 75%
• Risk of recurrence: 45-73%
• Patients with tumors initially confined to the uterus may be clinically aggressive
• Unclear role of adjuvant therapy
Diagnostic Criteria

- Coagulative tumor cell necrosis*
- Diffuse moderate to marked atypia*
  - Visible at low power
- High mitotic rate (>10MFs/10HPFs)*
- Diffuse hypercellularity
  - Any two of these criteria (*) diagnostic of leiomyosarcoma

## Diagnostic Criteria

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Tumor Necrosis</th>
<th>Mitotic Rate</th>
<th>Atypia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leiomyosarcoma</td>
<td>Present</td>
<td>Any Rate</td>
<td>Present or absent</td>
</tr>
<tr>
<td></td>
<td>Absent</td>
<td>≥ 10</td>
<td>Diffuse</td>
</tr>
<tr>
<td>STUMP</td>
<td>Questionable</td>
<td>Any Rate</td>
<td>Present or absent</td>
</tr>
<tr>
<td></td>
<td>Absent</td>
<td>&gt; 15</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>Absent</td>
<td>&lt; 10</td>
<td>Diffuse</td>
</tr>
<tr>
<td>Atypical LM</td>
<td>Absent</td>
<td>≤ 10</td>
<td>Diffuse</td>
</tr>
<tr>
<td>LM with increases mitotic activity</td>
<td>Absent</td>
<td>≤ 15</td>
<td>Absent</td>
</tr>
</tbody>
</table>
Uterine Smooth Muscle Tumors

Current Challenges

• Definition of necrosis
• Atypical/Bizarre leiomyoma
• Cellular/mitotically active leiomyoma
• Myxoid smooth muscle tumors
• Epithelioid smooth muscle tumors
• STUMP
• Intravenous leiomyomatosis
• Disseminated peritoneal leiomyomatosis
• Benign metastasizing leiomyoma
Interobserver Variability in the Interpretation of Tumor Cell Necrosis in Uterine Leiomyosarcoma

Diana Lim, MBBS, FRCPA,* Teresa Alvarez, MD,† Marisa R. Nucci, MD,‡ Blake Gilks, MD,§ Teri Longacre, MD,¶ Robert A. Soslow, MD,¶¶ and Esther Oliva, MD##

Tumor cell necrosis

- 34 cases
- 6 GYN pathologists
- TCN defined as: abrupt transition from viable to necrotic tumor, with tumor ghost cells. Hemorrhage and inflammation uncommon.
FIGURE 1. Full agreement in the diagnosis of TCN represented by cases 2 (A) and 27 (B). An abrupt transition from viable to nonviable tumor without interposed granulation or fibrocollagenous tissue. A residual perivascular rim of viable tumor cells is seen (A). Hyalinized tissue with scattered inflammatory cells, adjacent to viable tumor is present (B).
FIGURE 2. Partial agreement in the diagnosis of TCN represented by cases 21 (A) and 25 (B). A necrotic area with an abrupt transition from viable to nonviable tumor is seen which is also associated with hemorrhage and inflammation (A). Focus of necrosis in which “ghost” outlines of tumor cells are seen. However, an intervening rim of fibrocollagenous tissue with foci of hemorrhage separates the viable and nonviable areas (B).
Tumor cell necrosis

- Full agreement: 35% of cases
- Partial agreement: 47% of cases
- No agreement: 18% of cases
- Necrosis called “indeterminate” by at least one pathologist in 60% of cases
Smooth Muscle Tumors of Uncertain Malignant Potential “STUMPS”

- Tumor cell necrosis in ordinary leiomyoma
- Necrosis of uncertain type with 10 or more MFs/10 HPFs or marked diffuse atypia
- Marked diffuse atypia with uncertain or borderline mitotic counts
- Focal marked atypia and 10 or more MFs/10HPFs
“Low-Grade Leiomyosarcoma” and Late-Recurring Smooth Muscle Tumors of the Uterus: A Heterogenous Collection of Frequently Misdiagnosed Tumors Associated With an Overall Favorable Prognosis Relative to Conventional Uterine Leiomyosarcomas

Emanuela Veras,* Oliver Zivanovic,† Lindsay Jacks,‡ Daniel Chiappetta,* Martee Hensley,§ and Robert Soslow, MD*

Low Grade Leiomyosarcoma

- Local recurrences
- Histologic progression in recurrences
- LMS with indolent behavior
Low Grade Leiomyosarcoma

- 9% of LMS
- Heterogeneous group of lesions
- Atypical leiomyomas
- EES with smooth muscle differentiation
- Leiomyosarcomas
- Unrelated mesenchymal neoplasms
- Existence of low grade LMS regarded at best as debatable
A Nomogram to Predict Postresection 5-Year Overall Survival for Patients With Uterine Leiomyosarcoma

Oliver Zivanovic, MD; Lindsay M. Jacks, MS; Alexia Iasonos, PhD; Mario M. Leitao, Jr., MD; Robert A. Soslow, MD; Emanuela Veras, MD; Dennis S. Chi, MD; Nadeem R. Abu-Rustum, MD; Richard R. Barakat, MD; Murray F. Brennan, MD; and Martee L. Hensley, MD

Figure 2. This is the uterine leiomyosarcoma nomogram for 5-year overall survival. The mitotic index (asterisk) was modeled using log transformation; for display purposes, values were converted back to original scale (exponential; concordance probability [CP], 0.671; bootstrap-validated CP, 0.651).
Diagnostic Criteria

- Coagulative tumor cell necrosis*
- Diffuse moderate to marked atypia*
  - Visible at low power
- High mitotic rate (>10MFs/10HPFs)*
- Diffuse hypercellularity
  - Any two of these criteria (*) diagnostic of leiomyosarcoma

Pending Issues

- Uterine smooth muscle tumors poorly defined
- STUMP concept leads to significant uncertainty
- Low grade LMS need to be defined
- LGESS vs. HGESS need reappraisal on the basis of genetics
  - ESS (JAZF1-JJAZ1)
  - HG-ESS (YWHAE-FAM22A/B)
  - UES
THE END